CAFFEINE CITRATE
Clinical safety rating
cautionComprehensive clinical and safety monograph for CAFFEINE CITRATE (CAFFEINE CITRATE).
Caffeine is a methylxanthine that acts as a central nervous system stimulant. It competitively antagonizes adenosine receptors (A1 and A2A subtypes), leading to increased neuronal firing and neurotransmitter release. It also inhibits phosphodiesterase, resulting in elevated intracellular cAMP levels, and enhances calcium release from sarcoplasmic reticulum in muscle cells, promoting contractility.
| Metabolism | Primarily hepatic via cytochrome P450 1A2 (CYP1A2) to paraxanthine, theobromine, and theophylline. Also undergoes N-demethylation and oxidation. |
| Excretion | Renal excretion (86% as unchanged drug and metabolites; 1% as caffeine, 85% as paraxanthine and other metabolites). Fecal excretion is minimal (<2%). |
| Half-life | Adults: 3-6 hours (mean 5 hours). Neonates: 40-230 hours (mean 80 hours) due to immature hepatic clearance; clinical context: prolonged half-life in preterm infants requires dosing interval adjustment (usually 24 hours). |
| Protein binding | 25-36% bound primarily to albumin. Less bound compared to other methylxanthines (e.g., theophylline). |
| Volume of Distribution | 0.4-0.6 L/kg in adults. In neonates: 0.8-1.0 L/kg (higher Vd due to greater total body water). Clinical meaning: reflects distribution into total body water and tissues. |
| Bioavailability | Oral: 100% (rapidly and completely absorbed). Intravenous: 100% (given as citrate salt; bioavailability of caffeine base is equivalent). |
| Onset of Action | Intravenous (IV) bolus: 5-15 minutes to clinical effect (stimulation of respiratory drive). Oral: 30-60 minutes to clinical effect. |
| Duration of Action | IV: 4-6 hours (respiratory stimulation). Oral: 4-8 hours. Clinical notes: Duration may be prolonged in neonates (up to 24 hours) due to reduced clearance. |
| Molecular Weight | 194.19 |
20 mg/kg caffeine citrate (equivalent to 10 mg/kg caffeine base) IV over 30 minutes as a single loading dose, followed by a maintenance dose of 5-10 mg/kg caffeine citrate (2.5-5 mg/kg caffeine base) IV once daily, starting 24 hours after the loading dose.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. In severe renal impairment (GFR <30 mL/min/1.73 m²), use caution and consider reducing maintenance dose by 50% due to potential accumulation. |
| Liver impairment | In mild hepatic impairment (Child-Pugh class A), no adjustment. In moderate to severe hepatic impairment (Child-Pugh class B or C), reduce loading dose by 50% and maintenance dose by 50-75% due to decreased clearance. |
| Pediatric use | Neonates: Loading dose of 20 mg/kg caffeine citrate (10 mg/kg caffeine base) IV over 30 minutes, followed by maintenance of 5-10 mg/kg caffeine citrate (2.5-5 mg/kg caffeine base) IV or orally once daily. For infants >28 days and children: not routinely recommended; use with caution and adjust based on clinical response. |
| Geriatric use | No specific dose adjustment based on age alone. However, elderly patients may have reduced renal function and increased sensitivity to adverse effects (e.g., tachycardia, agitation). Monitor closely and consider starting at lower end of dosing range (e.g., 5 mg/kg caffeine citrate maintenance). |
| 1st trimester | Limited data suggest no major teratogenic risk; avoid high doses (≥300 mg/day) due to possible association with miscarriage. |
| 2nd trimester | May be used cautiously; monitor for maternal and fetal tachycardia. Avoid excessive intake. |
| 3rd trimester | Use with caution near term; caffeine may cause neonatal irritability and withdrawal. Reduced clearance in late pregnancy. |
Clinical note
Comprehensive clinical and safety monograph for CAFFEINE CITRATE (CAFFEINE CITRATE).
| Placental transfer | Readily crosses placenta; fetal levels approximate maternal levels due to limited fetal metabolism. |
| Breastfeeding | Caffeine enters breast milk (ratio ~0.5-0.75). Average levels in infants from moderate maternal intake are low. Monitor infant for irritability or sleep disturbances. Preterm infants may have reduced clearance. |
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | In the first trimester, high caffeine intake (>200-300 mg/day) is associated with a modestly increased risk of miscarriage. In the second and third trimesters, excessive caffeine may contribute to fetal growth restriction and low birth weight. No consistent evidence of major malformations. Caffeine citrate is generally avoided or used with caution during pregnancy. |
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, and signs of caffeine toxicity (tachycardia, arrhythmias, CNS stimulation). Fetal monitoring for heart rate and growth if chronic high doses used. Neonates should be observed for irritability, jitteriness, or sleep disturbances if exposed via breast milk. |
| Fertility Effects | High caffeine intake (>300 mg/day) may delay time to conception. No clear evidence of permanent fertility impairment. Caffeine citrate use for apnea of prematurity is not relevant to fertility. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to caffeine or any componentHistory of cardiac arrhythmiasUncontrolled hypertensionSevere anxiety disorderPeptic ulcer disease (active)Seizure disorder (unless on appropriate anticonvulsants)
| Precautions | Use with caution in patients with history of peptic ulcer disease, gastroesophageal reflux, or hiatal hernia, May exacerbate anxiety, insomnia, or cardiac arrhythmias, Monitor for caffeine toxicity in neonates: tachycardia, tachypnea, jitteriness, feeding intolerance, Slow clearance in premature infants; adjust dose based on plasma levels, Avoid sudden discontinuation to prevent withdrawal symptoms |
| Food/Dietary | No significant food interactions for caffeine citrate when administered intravenously. For oral administration, avoid excessive caffeine-containing foods or beverages (e.g., coffee, tea, soda) in breastfeeding mothers as it may pass into breast milk and affect the infant. |
| Clinical Pearls | Caffeine citrate is used for apnea of prematurity. Therapeutic levels: 5-25 mcg/mL. Dosing: loading dose 20 mg/kg IV, then maintenance 5 mg/kg/day. Monitor for tachycardia, jitteriness, feeding intolerance. Caffeine clearance is slower in neonates; dose adjustments may be needed with hepatic impairment or concomitant medications like cimetidine. Caffeine base vs. citrate: 1 mg caffeine base = 2 mg caffeine citrate. |
| Patient Advice | This medication stimulates breathing in premature infants and is given intravenously or orally. · Do not stop the medication abruptly without consulting the doctor. · Monitor your baby for any signs of fast heart rate, irritability, or poor feeding and report to healthcare provider. · Keep all follow-up appointments for blood level monitoring and assessment. · Inform the doctor about any other medications your baby is taking, as interactions may occur. |
Loading safety data…